Asia Fresh News

Asia Fresh Stories

Posts Tagged ‘Medical

Nopras Technologies Announces Schedule of Events at 2012 AAPS Annual Meeting and Exposition

leave a comment »

NOVI, Mich. /PRNewswire/ — Nopras Technologies Inc. (www.nopras-tech.com), a global management consulting firm to the pharmaceutical, biologics/biotechnology and medical device industries, has announced an event at the 2012 annual meeting and exposition of the American Association of Pharmaceutical Scientists (AAPS) in Chicago, IL.
“Nopras Technologies’ business model has changed significantly over the last few years as we have expanded our services globally,” said Lori Przybylo, Senior Account Manager of Nopras Technologies. “Many of our clients are interested in that evolution and we’re eager to talk with them about what it means in terms of these opportunities.”
“But we also want to emphasize the things that haven’t changed: our focus is still on delivering quality, regulatory and compliance solutions that have made us a leading global player in the life sciences industry. Examples of that work are what we are sharing at AAPS this year.”
Integrating technical, process, organizational, and business skills, Nopras Technologies industry experts enable life sciences companies to achieve optimal compliance and quality performance, operational excellence, and greater business value from their operations.
“We know the different challenges our clients face, the cultures in which they operate, and the unique demands that come with that,” stated Ms. Przybylo. “We don’t require a long, steep learning curve, and you will find that we bring a keen understanding, fresh perspectives and strategic abilities to the table from the ‘get go.'”
Nopras Technologies will be at Booth 2452 in the convention center exhibit hall, where it will host its traditional “Booth Bar” happy hour from 4:00 to 5:30 PM on Monday, October 15.
“I’m very proud of what we are sharing at AAPS,” said Lori Przybylo. “It shows the high-caliber work that any client can expect from Nopras Technologies.”
About Nopras Technologies, Inc.
Nopras Technologies has worked with clients globally in creating value to solve most difficult technical, quality, regulatory and compliance problems to advance new and existing medicines that improve human health. This success is based on our consultants’ abilities to provide industry expertise covering a wide range of technical disciplines, grown from a solid base of scientific and engineering fundamental understanding.
The company provides a broad spectrum of Regulatory, Compliance and Quality Services, Operational Improvement and Technical Services, Turnkey Solutions Services (Facility Start-Up and New Product Launch).
Its service portfolio covers FDA and foreign regulations/ guidelines and spans the full product development life cycle; from clinical development through market scrutiny.
The firm’s staff consists of well-credentialed physicians, scientists, engineers, and technical experts from industry leaders with extensive business and industry experience; many of whom are key opinion leaders, have held key management positions and have earned advanced degrees in medicine, science, engineering and business operate as a working team to integrate the different skill sets they offer.
Nopras Technologies assists clients’ advance promising drug candidates from conception through commercialization by providing technical, quality and regulatory support, assisting in process development and optimization, and manufacturing clinical-trial quantities of drug candidates and regulatory submissions.
The company is based in Novi, MI with offices in Fort Washington, PA, Shanghai, China and Singapore. For more information, visit http://www.nopras-tech.com.
Source: Nopras Technologies, Inc.

Written by asiafreshnews

October 16, 2012 at 3:55 pm

Posted in Uncategorized

Tagged with ,

Resverlogix Completes Enrollment In ASSURE Trial

leave a comment »

IVUS data will evaluate plaque regression in patients with Coronary Artery Disease
TSX Exchange Symbol: RVX
CALGARY, Ontario /PRNewswire/ — Resverlogix Corp. (TSX:RVX) today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease patients. ASSURE will evaluate the ability of RVX-208, Resverlogix’s BET protein inhibitor, to regress atherosclerotic disease versus placebo using intravascular ultrasound (IVUS) technology in patients with coronary artery disease (CAD).
“Completing enrollment of the ASSURE clinical trial marks another major milestone for Resverlogix as we aim to demonstrate the efficacy of RVX-208 in atherosclerotic plague regression,” stated Donald McCaffrey, president and chief executive officer of Resverlogix. “RVX-208 stimulates production of ApoA-I, increasing the functional HDL particles required for reverse cholesterol transport. We expect to announce top-line data from ASSURE in H1 2013.”
ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial led by the Cleveland Clinic. The primary trial endpoint will be measurement of atheroma volume reduction from baseline to 26 weeks measured by IVUS. Secondary objectives for ASSURE are evaluating the safety and tolerability of RVX-208 and effects of RVX-208 on HDL and non-HDL lipid parameters. Using IVUS data, we will also assess changes in plaque stability, an important factor affecting risk of myocardial infarction.
About RVX-208
RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains. It is currently in clinical study for the treatment of atherosclerosis. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of ApoA-I, the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. Because they are newly produced, these functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. RVX-208 is currently being evaluated in phase 2b studies for its ability to reverse and/or stabilize atherosclerotic disease. The drug candidate also has the potential to treat other indications, including neurodegenerative disorders.
About Resverlogix
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix’s epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune and neurodegenerative disorders. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit http://www.resverlogix.com.
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company’s products, the availability of government and insurance reimbursements for the Company’s products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at http://www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
Company Contacts:

Donald J. McCaffrey Sarah Zapotichny
President and CEO Director of Investor Relations
Resverlogix Corp. Resverlogix Corp.
Phone: +1-403-254-9252 Phone: +1-403-254-9252
Email: don@resverlogix.com Email: sarah@resverlogix.com

US Institutional Investors: Media:

Susan Noonan
Managing Partner Matt Middleman, M.D.
S.A. Noonan Communications, LLC Russo Partners, LLC
Phone: +1-212-966-3650 Phone: +1-212-845-4272
Email: susan@sanoonan.com Email: matt.middleman@russopartnersllc.com
(RVX.)
Source: Resverlogix Corp.

Written by asiafreshnews

September 27, 2012 at 2:53 pm

Posted in Uncategorized

Tagged with ,

Golden Meditech Holdings Limited Announces Updates on Medical Devices Subsidiary Latest Development

leave a comment »

HONG KONG/PRNewswire/ — Golden Meditech Holdings Limited (“Golden Meditech”, together with its subsidiaries collectively as the “Group”, 801.HK; 910801.TW), a leading integrated healthcare enterprise in China has reached agreements with certain investors which invested in China Bright Group Co. Limited (“China Bright”), non-wholly-owned medical devices subsidiary of Golden Meditech in August 2010. Under the revised agreements, the investors have agreed to expand the list of stock exchanges on which the securities of China Bright can be listed and to extend the initial public offering (“IPO”) timeframe to 26 February 2014 for China Bright to seek appropriate listing opportunities under the current market conditions, and at the same time, Golden Meditech will increase its equity holding in China Bright to 80.37%.
Mr. Kam Yuen, Chairman and Chief Executive Officer of Golden Meditech, said: “With the Chinese government pursuing to work for the betterment of medical practice, a number of favourable policies have been introduced, such as the ‘Level III General Hospital Accreditation and Administration Standards’ implemented by the Ministry of Health which demand hospital mangers to initiate autologous blood recovery programmes to alleviate surgical blood shortage. The demand for our key products, such as autologous blood recovery system is set to rise in the future to comply with these latest government developments.” Mr. Kam continued, “We consider that a separate listing of China Bright is in the best interests of the Group and the shareholders. This will allow China Bright to unlock its underlying value as well as seizing business opportunities elsewhere. The decision to extend the IPO timeframe has demonstrated commitment from investors over the value of China Bright amid market volatility. We will continue to monitor market conditions and launch the separate listing of China Bright at an appropriate time.”
Notice of Conference Call
Golden Meditech will hold a conference call for analysts and investors to discuss the above-mentioned development on Wednesday, 19 September, 2012 at 8:00 pm HKT / 8:00 am EST. To participate, please dial:
Hong Kong
Tel: + 852-2475-0994 China
Tel: 400-620-8038 or
800-819-0121 International
Tel: 1-718-354-1231 or
1-866-519-4004
Access code: 30636251
About Golden Meditech Holdings Limited
Golden Meditech Holdings Limited is China’s leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China’s healthcare industry both through organic growth and strategic expansion.
For inquiries, please contact:
Golden Meditech Holdings Limited
Investor Relations Department
Tel: (852) 3605 8180
Fax: (852) 3605 8181
Email: ir@goldenmeditech.com
Source: Golden Meditech,

Written by asiafreshnews

September 19, 2012 at 5:04 pm

Posted in Uncategorized

Tagged with ,

ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes

leave a comment »

CLEVELAND /PRNewswire/ — ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes.
(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )
“This grant will allow us to optimize our industry-leading cardiomyocyte assays,” said ChanTest’s Principal Investigator Andrew Bruening-Wright, Ph.D. “With our collaborators at FDA, DSEC, and Leadscope, Inc., we have improved predictivity models based on currently available ChanTest services. Our nonclinical models will only get better as we fully integrate cardiomyocyte-based assays.”
These cardiomyocyte assays are critical for improving the predictivity of nonclinical testing and reducing the use of animals as proposed in the NIH roadmap for drug discovery and the FDA’s critical path initiative. The grant will also fund development of automated instrument-based services to increase throughput and drive down costs to meet the needs of ChanTest customers.
Dr. Arthur “Buzz” Brown, founder and CEO of ChanTest and co-PI on the grant, added “ChanTest has assembled an expert team to ensure success of this grant. We’ll build on this success to improve drug discovery for other diseases in which ion channels play a critical role.”
About ChanTest – The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio.
Source: ChanTest

Written by asiafreshnews

September 18, 2012 at 11:27 am

Posted in Uncategorized

Tagged with ,

Centro Internacional de Cancer and MASEP Form First Infini(TM) Radiosurgery Center in Latin America

leave a comment »

The Infini™ Gamma Ray Radiosurgery System Now Available for First Time in Latin America
CITY OF INDUSTRY, Calif. /PRNewswire/ — MASEP Infini, an innovator in global medical technology, and Centro Internacional de Cancer, located in San Salvador, El Salvador, Central America, today announced that the Center has acquired the Infini™ Gamma Ray Radiosurgery System for its Radiosurgery Center. With this acquisition, Centro Internacional de Cancer becomes the first center in Latin America to offer its patients the latest generation noninvasive treatment for brain disorders in the form of the Infini™ System that combines advanced Treatment Planning Software with patented Rotary Focusing Technology. This combination allows MASEP Infini to provide clinicians with state-of-the-art Radiosurgery Systems at reduced life cycle costs.
“This is a historic moment for El Salvador and Central America since this is the first high precision Intracranial Radiosurgery Program in the region. We evaluated different technologies, and came to the conclusion that the Infini, because of its focusing rotating capabilities, will allow the best treatment of intracranial tumors, vascular malformations, and other complex brain diseases, such as epilepsy and symptoms of Parkinson’s disease in a noninvasive way. This is a giant leap for neurosurgery in this region,” said Dr Eduardo Lovo, neurosurgeon, and Chief of Radiosurgery at the Cancer Center.
The Infini™ Gamma Ray Stereotactic Radiosurgery System received FDA 510(k) clearance in March 2011. It is a high-tech system with automatic features and unparalleled dose-sculpturing abilities. Stereotactic gamma ray radiosurgery focuses radiation on specific areas of the brain to treat tumors and malformations.
“The Infini™ system automates treatment delivery, which provides physicians with outstanding tools to offer the most accurate therapeutic interventions,” said Jose Lopez, vice president of MASEP Infini. “Physicians treating patients with brain disorders do not want to expose brain tissue to unnecessary radiation. That’s why using multipurpose radiation equipment on brain patients is not the optimal choice.”
Brain tumors affect about 190,000 Americans a year; there are over 100 different types of brain tumors. Finding the most effective treatment requires expert medical care and state-of-the-art medical equipment. Brain tumors represent a significant burden to the healthcare system and can devastate the lives of patients and their families. Gamma ray radiosurgery is a safe, effective, and non-surgical approach for the treatment of certain types of brain tumors.
“The International Cancer Center took a leadership role in Central America almost two years ago by incorporating highly advanced radiation technology for cancer treatment and initiating a complete body radiosurgical program. The addition of the Infini Gamma Ray Radiosurgery System comes as a perfect complement to our current technology, solidifying our excellence in cancer care. The system will be installed in March of 2013,” said Dr Rodrigo Brito, Director and President of the International Cancer Center.
MASEP Infini is a company specializing in innovative approaches in order to bring life-saving technologies to more patients by offering cost-effective solutions that do not compromise therapeutic safety or efficacy. MASEP Infini is based in City of Industry, California, and is focused on Stereotactic gamma ray radiosurgery.
Contact: Jose Lopez MASEP Infini +1-626-965-3200, sales@masepinfini.com
Source: MASEP Infini

Written by asiafreshnews

September 6, 2012 at 3:08 pm

Posted in Uncategorized

Tagged with ,